Burlingame, CA, United States

Juvaris BioTherapeutics

www.juvaris.com
Burlingame, CA, United States
SEARCH FILTERS
Time filter
Source Type

Fairman J.,Juvaris BioTherapeutics | Fairman J.,SutroVax | Liu K.H.,Cornell University | Menne S.,Cornell University | Menne S.,Georgetown University
BMC Cancer | Year: 2017

Background: Approximately 250 million people worldwide are chronically infected with hepatitis B virus (HBV) and more than half of the hepatocellular carcinoma (HCC) cases are attributed to this infection. As HCC has a high mortality rate, and current treatment options are remarkably limited, the development of new therapeutic treatment strategies is warranted. Methods: In this study, woodchucks infected with woodchuck hepatitis virus (WHV), and with pre-existing liver tumors, were used as a model to investigate if complexes of cationic liposomes and non-coding DNA (JVRS-100) were effective in treatment of HCC. Results: It was observed that the high serum viral load that is present in a typical chronic WHV infection (i.e., approximately 100-fold higher than human viral loads) results in immune suppression and resistance to treatment with JVRS-100. Treatment of woodchucks with lower serum viral load that more closely matched with the viral load usually seen in human HBV infection appears a better model for immunotherapeutic development based on the responsiveness to JVRS-100 treatment. In the latter case, marked declines in WHV DNA and WHV surface antigen were determined over the 12-week treatment period and WHV markers stayed suppressed during most time points of the 12-week follow-up period. Even more remarkably, the formation of new liver tumors was not observed in woodchucks treated with a well-tolerated dose of JVRS-100, as compared to several new tumors that developed in vehicle-treated control animals. Conclusions: Although there was little decrease in the volumes of the liver tumors existing at the time of treatment, it is generally accepted that preventing the spread and metastasis of almost always fatal cancers such as HCC and thus, reducing it to a chronic and treatable disease can also be a successful therapeutic approach. The results in woodchucks warrant the investigation of JVRS-100 as an intervention to prevent liver cancer in patients chronically infected with HBV and at high risk for HCC development. © 2017 The Author(s).


Dong L.,Centers for Disease Control and Prevention | Liu F.,Centers for Disease Control and Prevention | Fairman J.,Colby Pharmaceutical Company | Hong D.K.,Stanford University | And 8 more authors.
Vaccine | Year: 2012

The development of pre-pandemic influenza A H5N1 vaccines that confer both antigen-sparing and cross-clade protection are a high priority given the limited worldwide capacity for influenza vaccine production, and the antigenic and genetic heterogeneity of circulating H5N1 viruses. The inclusion of potent adjuvants in vaccine formulations may achieve both of these aims. Here we show that the addition of JVRS-100, an adjuvant consisting of cationic liposome-DNA complexes (CLDC) to a clade 1-derived H5N1 split vaccine induced significantly higher virus-specific antibody than unadjuvanted formulations, with a >30-fold dose-sparing effect and induction of increased antigen-specific CD4 + T-cell responses in mice. All mice that received one dose of adjuvanted vaccine and subsequent H5N1 viral challenges exhibited mild illness, lower lung viral titers, undetectable spleen and brain viral titers, and 100% survival after either homologous clade 1 or heterologous clade 2 H5N1 viral challenges, whereas unadjuvanted vaccine recipients showed significantly increased weight loss, viral titers, and mortality. The protective immunity induced by JVRS-100 adjuvanted H5N1 vaccine was shown to last for over one year without significant waning. Thus, JVRS-100 adjuvanted H5N1 vaccine elicited enhanced humoral and T-cell responses, dose-sparing, and cross-clade protection in mice. CLDC holds promise as an adjuvant for human pre-pandemic inactivated H5N1 vaccines. © 2011 Elsevier Ltd.


Bernstein D.I.,University of Cincinnati | Earwood J.D.,University of Cincinnati | Bravo F.J.,University of Cincinnati | Cohen G.H.,University of Pennsylvania | And 4 more authors.
Vaccine | Year: 2011

Genital herpes simplex virus (HSV) infections are common but results from vaccine trials with HSV-2 glycoprotein D (gD) have been disappointing. We therefore compared a similar HSV gD2 vaccine, to a further truncated gD2 vaccine, to a vaccine with gD2 plus gB2 and gH2/gL2 and to a vaccine with only gB2 and gH2/gL2 in a guinea pig model of genital herpes. All vaccines were administered with cationic liposome-DNA complexes (CLDC) as an adjuvant. All vaccines significantly decreased the severity of acute genital disease and vaginal virus replication compared to the placebo group. The majority of animals in all groups developed at least one episode of recurrent disease but the frequency of recurrent disease was significantly reduced by each vaccine compared to placebo. No vaccine was significantly more protective than gD2 alone for any of the parameters described above. No vaccine decreased recurrent virus shedding. When protection against acute infection of dorsal root ganglia and the spinal cord was evaluated all vaccines decreased the per cent of animal with detectable virus and the quantity of virus but again no vaccine was significantly more protective than another. Improvements in HSV-2 vaccines may require inclusion of more T cell targets, more potent adjuvants or live virus vaccines. © 2011 Elsevier Ltd.


Ireland R.,U.S. National Institutes of Health | Olivares-Zavaleta N.,U.S. National Institutes of Health | Warawa J.M.,U.S. National Institutes of Health | Gherardini F.C.,U.S. National Institutes of Health | And 5 more authors.
PLoS Pathogens | Year: 2010

Protection against virulent pathogens that cause acute, fatal disease is often hampered by development of microbial resistance to traditional chemotherapeutics. Further, most successful pathogens possess an array of immune evasion strategies to avoid detection and elimination by the host. Development of novel, immunomodulatory prophylaxes that target the host immune system, rather than the invading microbe, could serve as effective alternatives to traditional chemotherapies. Here we describe the development and mechanism of a novel pan-anti-bacterial prophylaxis. Using cationic liposome non-coding DNA complexes (CLDC) mixed with crude F. tularensis membrane protein fractions (MPF), we demonstrate control of virulent F. tularensis infection in vitro and in vivo. CLDC+MPF inhibited bacterial replication in primary human and murine macrophages in vitro. Control of infection in macrophages was mediated by both reactive nitrogen species (RNS) and reactive oxygen species (ROS) in mouse cells, and ROS in human cells. Importantly, mice treated with CLDC+MPF 3 days prior to challenge survived lethal intranasal infection with virulent F. tularensis. Similarly to in vitro observations, in vivo protection was dependent on the presence of RNS and ROS. Lastly, CLDC+MPF was also effective at controlling infections with Yersinia pestis, Burkholderia pseudomallei and Brucella abortus. Thus, CLDC+MPF represents a novel prophylaxis to protect against multiple, highly virulent pathogens.


Bernstein D.I.,University of Cincinnati | Farley N.,University of Cincinnati | Bravo F.J.,University of Cincinnati | Earwood J.,University of Cincinnati | And 3 more authors.
Vaccine | Year: 2010

Herpes simplex virus (HSV) infections are common but there is no vaccine available. We evaluated cationic liposome-DNA complexes (CLDC) as an adjuvant for an HSV gD2 vaccine and compared it to an MPL/Alum adjuvant in a guinea pig model of genital herpes. The addition of CLDC to the gD2 vaccine significantly decreased acute and recurrent disease and most importantly the number of days with recurrent virus shedding compared to gD2 alone. Reductions in these outcomes were also detected when gD2 + CLDC was compared to gD2 + MPL/Alum. When the vaccine and adjuvants were evaluated as therapeutic vaccines, they were ineffective. CLDC enhanced protection compared to MPL/Alum and is the first vaccine to reduce recurrent virus shedding, a key to decreasing the spread of HSV-2. © 2009 Elsevier Ltd. All rights reserved.


Juvaris BioTherapeutics | Entity website

Legal Welcome to the Juvaris BioTherapeutics, Inc. web site ...


News Article | November 2, 2007
Site: venturebeat.com

Bas Medical raises $20M for heart-failure drug — San Mateo, Calif.-based Bas Medical, a biotech developing drugs based on a hormone called relaxin, raised $20 million in a third funding round, VentureWire reports (subscription required). Investors included Domain Associates, Kleiner Perkins Caufield & Byers and Sears Capital Management. Relaxin is a natural peptide hormone whose levels typically rise during pregnancy, boosting heart and kidney function. Bas Medical figures that the hormone may be useful in treating disorders such as acute heart failure and preeclampsia, a dangerous pregnancy complication involving high blood pressure and kidney failure. The company is currently carrying out mid-stage human tests of the peptide in both conditions. Bas Medical also announced that it hired Stan Abel as its new CEO. Abel previously served as CFO for both Peninsula Pharmaceuticals and its spinout, Cerexa. Juvaris is developing vaccines against infectious disease and cancer using adjuvants — substances that enhance immune response, and thus the activity of vaccines — made from complexes formed by out of complexes of DNA and fatty molecules called lipids. We previously covered the company here.


Juvaris BioTherapeutics | Entity website

2014 Juvaris BioTherapeutics


Juvaris BioTherapeutics | Entity website

Overview of Juvaris' Technology Platform The Juvaris technology platform consists of cationic lipid-DNA complexes in development to treat infectious diseases and cancers. The DNA component contains immunostimulatory CpGs and non-CpG motifs, but does not code for any genes and is thereby distinguished from gene therapy and traditional DNA vaccine technologies ...

Loading Juvaris BioTherapeutics collaborators
Loading Juvaris BioTherapeutics collaborators